about
Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesisEnhanced anti-HCV activity of interferon alpha 17 subtypeAlginate hydrogel protects encapsulated hepatic HuH-7 cells against hepatitis C virus and other viral infectionsCoexistence of SHV-4- and TEM-24-producing Enterobacter aerogenes strains before a large outbreak of TEM-24-producing strains in a French hospitalMolecular characterization of glycopeptide-resistant enterococci from hospitals of the picardy region (france).Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions.Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus.Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study.The treatment response of chronically hepatitis C virus-infected patients depends on interferon concentration but not on interferon gene expression in peripheral blood mononuclear cells.Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy.Are trans-complementation systems suitable for hepatitis C virus life cycle studies?Simeprevir for the treatment of hepatitis C virus infection.The expression of HCV-associated host factors is dependent on the hepatoma cell line used in HCV studies.Natural selection of adaptive mutations in non-structural genes increases trans-encapsidation of hepatitis C virus replicons lacking envelope protein genes.An appropriate selection of a 3D alginate culture model for hepatic Huh-7 cell line encapsulation intended for viral studies.Factors associated with delayed screening of contacts of tuberculosis cases in the Somme, France.X4 Tropic Virus Prediction Is Associated with a Nadir CD4 T-Cell Count below 100 Cells/mm.Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins.Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus.Positive effect of the hepatitis C virus nonstructural 5A protein on viral multiplication.Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity.Emergence of a genomic variant of the recombinant 2k/1b strain during a mixed Hepatitis C infection: a case report.Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy.Variability of the nonstructural 5A protein of hepatitis C virus type 3a isolates and relation to interferon sensitivity.Molecular characterisation and mechanisms of resistance of multidrug-resistant human Salmonella enterica serovar Typhimurium isolated in Amiens (France).Comparison of MALDI-ToF MS with the Rapidec Carba NP test for the detection of carbapenemase-producing Enterobacteriaceae.Personalized therapy for chronic viral hepatitis C in the naive patient: How can we optimize treatment duration as a function of viral genotype?Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital.Prospective evaluation of a screening algorithm for carbapenemase-producing EnterobacteriaceaeA simple and automated HPLC method for determination of total hydroxyproline in urine. Comparison with excretion of pyridinolines[Research of type 1, 2 and 3 hepatitis C virus specific antibodies in relation to the viral genotype in chronically infected patients]Synthesis and Study of New Quinolineaminoethanols as Anti-Bacterial DrugsAnti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 hospitalized patients and asymptomatic carriers
P50
Q27469667-33FCC633-CA26-4B0B-8294-867401CC781DQ27488764-E3C32081-D529-49B1-B90D-FE1E54E53D7FQ28543716-629510F4-2A66-41EB-AC87-E82B11E789B2Q33972569-8C1AE64E-24EF-483D-9C40-3602663D5F94Q34259945-C8C2D697-BB74-431A-8FA6-25AF090AFB0FQ34295953-0EF46542-8EB9-4FC6-9332-86341242AE9FQ34936072-4297924F-2338-4838-A5F0-86D9009D14ACQ35073559-DF572CC6-B1D4-4975-9B22-8BB24EFCC310Q35689238-C0F83659-CF33-4244-B8DE-D0B7C65372FBQ37780054-3E8E4EDA-FDB7-4859-BAFB-27A9E581EC3FQ38089384-E05162D6-1596-4A81-B0A0-A8A5DF82E10CQ38247985-94900DD3-4001-49CA-8091-3116966375A3Q39084971-3B8B63F0-E883-4386-AA03-3FD8EAACDA13Q39216626-E170AF95-6A31-4443-B193-ECF6264636DAQ39298414-4479C2EE-5B99-4576-AC5B-25FA5778B1E1Q39422972-DF703FAB-D2BF-4219-BE69-C21DD833AFF2Q39443047-3B19460E-8A42-4BBC-8406-EA232EB2403DQ40094231-D3696701-36B0-4338-AF57-09AC0059CD80Q42979198-936239D0-0C6B-4390-B489-B29CB89745C7Q42985967-1BB75E55-DEC3-401B-A8ED-195AF48ED5B8Q42988613-36A30E4B-1AF7-426D-B9DC-1EF827A84E6FQ42994712-3540E21A-D715-4DF5-81F6-D65E7317CB20Q42999765-A71B4C19-B5E4-43A2-B4CF-CAA92BF68D05Q43036775-9F87FA1D-10FB-4DB8-B1A8-6EA435E433E6Q46669604-51AE89E1-0E17-46D9-B308-423E03D93DBCQ48242009-E3C9D02E-A5CF-4AE4-A90D-C54EC03B836CQ50569920-6592EF78-6E93-459C-9D4C-285D2CE795EFQ53861469-27396F24-D67D-4985-B2B1-405772279723Q58616864-73457C15-CFF9-40AA-9382-78B5DE8228BCQ71956076-9F0F2122-C13F-4F60-B768-602579E2CEADQ73211761-1A3CE91C-7542-4FB2-A065-F5B8AD96727DQ92880108-75370C7E-FEE2-4759-A5D1-35F8C677C468Q95604311-3C2BB8F0-C604-4C42-AD18-525F8C2A8019
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
S Castelain
@ast
S Castelain
@en
S Castelain
@es
S Castelain
@nl
S Castelain
@sl
type
label
S Castelain
@ast
S Castelain
@en
S Castelain
@es
S Castelain
@nl
S Castelain
@sl
prefLabel
S Castelain
@ast
S Castelain
@en
S Castelain
@es
S Castelain
@nl
S Castelain
@sl
P106
P31
P496
0000-0002-2670-3148